. Author manuscript; available in PMC: 2021 Nov 1.

Published in final edited form as: Int J Gynecol Cancer. 2020 May 6;30(11):1811–1823. doi: 10.1136/ijgc-2020-001309

Table 3.

Pre-treatment molecular markers investigated for their association with disease regression and/or recurrence.

Molecular marker	Regression	Recurrence	No association
PR	High ^{(137, 140)}		^{(129, 139)}
PRβ	High ⁽¹⁴¹⁾		^{(139, 142)}
Glandular PRβ		High ^{(135, 136)}	⁽¹⁴²⁾
Stromal PRβ			⁽¹⁴²⁾
Glandular PRα		Low ⁽¹³⁶⁾	⁽¹⁴²⁾
Stromal PRα		Low ^{(135, 136)}	⁽¹⁴²⁾
Glandular PRα:PRβ		≤1 ⁽¹³⁶⁾
Stromal PRα:PRβ		≤1 ⁽¹³⁶⁾
ERα	High ⁽¹⁴⁰⁾		^{(129, 135, 139, 142)}
ERβ			^{(135, 142)}
MMR status	Proficient ⁽¹³²⁾
HSPA5/GRP78	Low ⁽¹⁴³⁾
Ki67	Low ⁽¹³⁹⁾		⁽¹²⁹⁾
p53	Low ⁽¹³⁷⁾
AR			⁽¹⁴²⁾
BAX			⁽¹³⁵⁾
BCL2			^{(135, 137, 139–141)}
Cleaved caspase			⁽¹³⁹⁾
COX2			⁽¹⁴⁰⁾
MLH1			⁽¹⁴⁰⁾
PAX2			^{(135, 141, 144)}
PTEN			^{(135, 141, 144)}
CA-125			⁽¹³⁴⁾
Estradiol			⁽¹³⁶⁾